Vaccibody As Stock Gross Profit
| VACCDelisted Stock | USD 2.23 0.04 1.83% |
Vaccibody As fundamentals help investors to digest information that contributes to Vaccibody's financial success or failures. It also enables traders to predict the movement of Vaccibody Stock. The fundamental analysis module provides a way to measure Vaccibody's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaccibody stock.
Vaccibody |
Vaccibody As Company Gross Profit Analysis
Vaccibody's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Vaccibody Gross Profit | 44.7 M |
Most of Vaccibody's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaccibody As is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Vaccibody As reported 44.7 M of gross profit. This is 98.01% lower than that of the Biotechnology sector and 95.3% lower than that of the Health Care industry. The gross profit for all Norway stocks is 99.84% higher than that of the company.
Vaccibody Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaccibody's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaccibody could also be used in its relative valuation, which is a method of valuing Vaccibody by comparing valuation metrics of similar companies.Vaccibody is currently under evaluation in gross profit category among its peers.
Vaccibody Fundamentals
| Return On Equity | -0.23 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (77.18) % | |||
| Current Valuation | 32.03 M | |||
| Shares Outstanding | 38.55 M | |||
| Shares Owned By Insiders | 3.45 % | |||
| Shares Owned By Institutions | 49.84 % | |||
| Number Of Shares Shorted | 159.22 K | |||
| Price To Earning | 12.63 X | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 2.31 X | |||
| Revenue | 44.7 M | |||
| Gross Profit | 44.7 M | |||
| EBITDA | 869 K | |||
| Net Income | 5.32 M | |||
| Cash And Equivalents | 192.33 M | |||
| Cash Per Share | 5.17 X | |||
| Total Debt | 8.77 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 18.60 X | |||
| Book Value Per Share | 5.64 X | |||
| Cash Flow From Operations | (14.43 M) | |||
| Short Ratio | 0.08 X | |||
| Earnings Per Share | (1.59) X | |||
| Target Price | 9.31 | |||
| Number Of Employees | 33 | |||
| Beta | -0.39 | |||
| Market Capitalization | 192.73 M | |||
| Total Asset | 270.2 M | |||
| Retained Earnings | (103.24 M) | |||
| Working Capital | 200.8 M | |||
| Z Score | 13.71 | |||
| Net Asset | 270.2 M |
About Vaccibody Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaccibody As's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaccibody using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaccibody As based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| S | SentinelOne | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |